Abstract A052: Safety, immunogenicity and resistance of in situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial
Year: 2026
Type: conference-abstract
Source: Cancer Immunology Research
Authors: Steven V. Luong, Hisashi Kanemaru, Andrew S . Lim, Shelly X. Bian, Stella Yoo, Yukari Mizukami, Rowena Vergara, Maria E. Nelson, Stephen F. Sener, Andres M. Salazar, Tibor Keler, Diane Young, William D. Wallace, Ming Li, Yang Liu, Qiuyang Zhang, Chris X. Chen, Sheng Li, Evanthia Roussos Torres, Anastasia Martynova, Danielle Sterrenberg, Anthony El-Khoueiry, Daphne B. Stewart, Jason C. Ye, James S. Hu, Gino K. In, Fumito Ito
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7130400584
Cites:
Cited by:
Related to: